Publications by authors named "Olivia Criss"
Article Synopsis
- - The FDA has approved lecanemab as a treatment for Alzheimer's disease, targeting Aβ protofibrils and showing promise in slowing disease progression in mild cases.
- - In clinical trials, lecanemab demonstrated a modest improvement in clinical decline and a reduction of amyloid proteins, although the significance of this impact is still debated.
- - While lecanemab offers benefits, it comes with serious risks like brain swelling and microhemorrhages, and it is quite expensive at $26,500 per year, raising questions about access to treatment.
